Keywords: accentia, licenses, global, rights, revimmune, usa, acquired

Accentia licenses global rights to Revimmune

Article | 05 March 2007

Print This

The USA's Accentia has acquired exclusive global rights to Revimmune, a pharmaceutical treatment in late-stage development for a variety of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in